Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease.

Soldan A, Pettigrew C, Cai Q, Wang J, Wang MC, Moghekar A, Miller MI, Albert M; BIOCARD Research Team.

Neurobiol Aging. 2017 Dec;60:164-172. doi: 10.1016/j.neurobiolaging.2017.09.002. Epub 2017 Sep 11.

PMID:
28968586
2.

Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.

Pettigrew C, Soldan A, Sloane K, Cai Q, Wang J, Wang MC, Moghekar A, Miller MI, Albert M; BIOCARD Research Team.

Neuroimage Clin. 2017 Aug 25;16:439-446. doi: 10.1016/j.nicl.2017.08.022. eCollection 2017.

3.

A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium.

Gross AL, Hassenstab JJ, Johnson SC, Clark LR, Resnick SM, Kitner-Triolo M, Masters CL, Maruff P, Morris JC, Soldan A, Pettigrew C, Albert MS.

Alzheimers Dement (Amst). 2017 May 30;8:147-155. doi: 10.1016/j.dadm.2017.05.003. eCollection 2017.

4.

Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior.

Soldan A, Pettigrew C, Moghekar A, Albert M; BIOCARD Research Team.

J Int Neuropsychol Soc. 2016 Nov;22(10):968-977.

5.

Cognitive reserve and cortical thickness in preclinical Alzheimer's disease.

Pettigrew C, Soldan A, Zhu Y, Wang MC, Brown T, Miller M, Albert M; BIOCARD Research Team.

Brain Imaging Behav. 2017 Apr;11(2):357-367. doi: 10.1007/s11682-016-9581-y.

PMID:
27544202
6.

Cortical thickness in relation to clinical symptom onset in preclinical AD.

Pettigrew C, Soldan A, Zhu Y, Wang MC, Moghekar A, Brown T, Miller M, Albert M; BIOCARD Research Team.

Neuroimage Clin. 2016 Jun 15;12:116-22. doi: 10.1016/j.nicl.2016.06.010. eCollection 2016.

7.

Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults.

Wennberg AM, Spira AP, Pettigrew C, Soldan A, Zipunnikov V, Rebok GW, Roses AD, Lutz MW, Miller MM, Thambisetty M, Albert MS.

J Neurol Sci. 2016 Jun 15;365:89-95. doi: 10.1016/j.jns.2016.04.017. Epub 2016 Apr 14.

8.

Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.

Soldan A, Pettigrew C, Cai Q, Wang MC, Moghekar AR, O'Brien RJ, Selnes OA, Albert MS; BIOCARD Research Team.

JAMA Neurol. 2016 Jun 1;73(6):698-705. doi: 10.1001/jamaneurol.2016.0194.

9.

Integrated molecular, physiological and in silico characterization of two Halomonas isolates from industrial brine.

Carlson RP, Oshota O, Shipman M, Caserta JA, Hu P, Saunders CW, Xu J, Jay ZJ, Reeder N, Richards A, Pettigrew C, Peyton BM.

Extremophiles. 2016 May;20(3):261-74. doi: 10.1007/s00792-015-0806-6. Epub 2016 Feb 18.

PMID:
26888357
10.

The role of working memory capacity and interference resolution mechanisms in task switching.

Pettigrew C, Martin RC.

Q J Exp Psychol (Hove). 2016 Dec;69(12):2431-2451.

11.

African Americans and Clinical Research: Evidence Concerning Barriers and Facilitators to Participation and Recruitment Recommendations.

Hughes TB, Varma VR, Pettigrew C, Albert MS.

Gerontologist. 2017 Apr 1;57(2):348-358. doi: 10.1093/geront/gnv118.

PMID:
26553736
12.

Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.

Pettigrew C, Soldan A, Moghekar A, Wang MC, Gross AL, O'Brien R, Albert M.

Neuropsychologia. 2015 Nov;78:63-72. doi: 10.1016/j.neuropsychologia.2015.09.024. Epub 2015 Sep 21.

13.

Albumin Administration in Acute Ischemic Stroke: Safety Analysis of the ALIAS Part 2 Multicenter Trial.

Hill MD, Martin RH, Palesch YY, Moy CS, Tamariz D, Ryckborst KJ, Jones EB, Weisman D, Pettigrew C, Ginsberg MD.

PLoS One. 2015 Sep 1;10(9):e0131390. doi: 10.1371/journal.pone.0131390. eCollection 2015.

14.

Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease.

Soldan A, Pettigrew C, Lu Y, Wang MC, Selnes O, Albert M, Brown T, Ratnanather JT, Younes L, Miller MI; BIOCARD Research Team.

Hum Brain Mapp. 2015 Jul;36(7):2826-41. doi: 10.1002/hbm.22810. Epub 2015 Apr 16.

15.

Nurturing the next generation.

Pettigrew CA.

Trends Mol Med. 2015 Feb;21(2):53-4. No abstract available.

PMID:
25662029
16.

Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial.

Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, Benavente OR; SPS3 Investigators.

Lancet Neurol. 2014 Dec;13(12):1177-85. doi: 10.1016/S1474-4422(14)70224-8. Epub 2014 Oct 23.

17.

Role for Memory Capacity in Sentence Comprehension: Evidence from Acute Stroke.

Pettigrew C, Hillis AE.

Aphasiology. 2014;28(10):1258-1280.

18.

Cognitive declines in healthy aging: evidence from multiple aspects of interference resolution.

Pettigrew C, Martin RC.

Psychol Aging. 2014 Jun;29(2):187-204. doi: 10.1037/a0036085.

PMID:
24955989
19.

A defining time for sepsis.

Pettigrew CA.

Trends Mol Med. 2014 Apr;20(4):191. No abstract available.

PMID:
24698493
20.

C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.

Elkind MS, Luna JM, McClure LA, Zhang Y, Coffey CS, Roldan A, Del Brutto OH, Pretell EJ, Pettigrew LC, Meyer BC, Tapia J, White C, Benavente OR; LIMITS Investigators.

Stroke. 2014 Mar;45(3):707-16. doi: 10.1161/STROKEAHA.113.004562. Epub 2014 Feb 12.

Supplemental Content

Loading ...
Support Center